Welcome to today’s Nasdaq futures analysis for Friday, January 31, 2025! ? As we wrap up the first month of the year, the market presents high-probability setups with potential gap closures and directional movements. Here’s what we are watching today: ? Long Opportunities: Price holding above 21,770–21,800 could lead to a move toward 21,860 and 22,075. If the market retraces to the 21,680–21,608 range, it could provide strong bullish momentum. ? Short Setups: A rejection near 21,860–21,900 could trigger a drop toward 21,610 and lower. If price breaks 21,600 before the market open, we may see continuation toward 21,450. ? Market Insights: With gap closures in play, today’s session offers multiple trading scenarios. Whether the price continues its bullish structure or faces strong resistance, risk management will be essential. ? Join our daily lives at 9:30 AM (NY time) for real-time market analysis and Q&A. Let us know in the comments what other assets you’d like us to analyze or if you’re interested in swing trading strategies! ? Subscribe now for expert trading insights, daily updates, and actionable strategies. Let’s close the week with precision!
Key arguments supporting the idea • Doximity is a leader in the rapidly growing telemedicine industry. • The results for Q3 FY2025 may once again impress investors due to the use of AI tools. • Maintaining high growth rates of financial indicators and a strong balance sheet in the medium term. Doximity is the owner of the largest medical social network in the U.S, bearing the same name. Founded in 2010, the company has become something like "LinkedIn for doctors," providing the medical community with tools for professional communication, telemedicine, exchanging clinical information, and finding career opportunities. The platform covers over 90% of U.S. doctors, offering access to more than 100,000 current job openings for medical professionals. Investment Thesis Telemedicine is one of the fastest-growing industries , with an annual growth rate of 24% expected from 2022 to 2032, according to Grand View Research. Unlike other public companies in the telemedicine field, such as Teladoc (TDOC), GoodRx (GDRX), and Amwell (AMWL), Doximity is the only profitable company. One of Doximity's key advantages is its ability to generate revenue not only from telemedicine services but also from targeted advertising and marketing solutions aimed at medical professionals, which allows the company to effectively compete in the market. According to the Doximity’s investor presentation, company estimates the total market for telemedicine, pharmaceutical marketing, and healthcare recruitment at $18.5 billion, highlighting significant opportunities for growth and expansion. The results for Q3 FY2025 may once again impress investors with revenue and EPS growth driven by AI solutions. The number of major clients generating over $500k annually increased from 92 to 103 as of Q2 FY2025, and these clients account for approximately 83% of the company's total revenue. The company has a good chance of repeating the dynamics of previous quarters due to AI solutions that increase customer engagement and improve targeted advertising. The company reported that over one million requests were made to Doximity GPT in Q2 FY2025. The increase in user engagement, supported by tools like Newsfeed and Client Portal, significantly improves user loyalty and increases the value of advertising opportunities for pharmaceutical companies. Today over 600,000 doctors actively use Doximity tools for their daily tasks. For Q3 FY2025, the company expects 13% YoY revenue growth and 15% YoY EPS growth. Maintaining high growth rates of financial indicators and a strong balance sheet. Over the past 5 years, the revenue CAGR has been 32%, and net income has increased more than 14-fold. The company has a strong balance sheet with $800 million in cash and debt of $13 million, with a current ratio of 7.2. Additionally, by the end of Q2 FY2025, the gross margin, adjusted EBITDA, and net margin reached record levels, at 90%, 53%, and 32%, respectively. According to the FactSet consensus, double-digit growth rates are expected to continue over the next three years, with forecasted revenue growth of 13.6% and adjusted EPS growth of 21.3% in FY2025. We maintain a Buy rating on DOCS stock with a price target of $66. A stop-loss order is recommended at $45.
Dealing Range BSL is taken out. Awaiting for orders in the Bullish Candle to be eaten by sellers. Then Buyers will try buy it up. (Needs weak demand) Then Sellers to enter once more and straight to SSL.
Gold makes a new all time high while most of the tech stocks and bitcoin are at short term resistance levels. Do we get another correction in the markets starting tomorrow Feb 1 as tariffs take place?
? Prepare to BUY Spot DOTUSDT (M & 3M Cycle Combination) ? DOTUSDT is a fundamentally strong asset, now entering an ideal accumulation phase in its M & 3M cycle! ? ? Market Overview: Fundamentally, DOT remains a relatively safe investment with a strong ecosystem and development progress. Technically, the current M cycle correction presents a great opportunity for accumulation before the next expansion phase. ? Trade Plan: ? Entry Point: $4.8 - $6.3, or accumulate at lower prices if possible. ? Target: $15 – Mid-term projection based on cycle progression. ⏳ Hold Time: 6-12 months, aligned with the expected M & 3M cycle growth phase. ? Strategy: Accumulate progressively within the recommended price range. Monitor market trends and breakout confirmations for optimal positioning. Maintain a mid-term approach, avoiding short-term noise. ? DOTUSDT presents a solid mid-term opportunity – Start accumulating now! ?
The latest Ethereum analysis shows a compelling breakout from a symmetrical triangle, presenting a clear trading opportunity. This move comes after a prolonged period of consolidation, with the price now aiming for higher levels. The first price target (TP1) is set at 3,700, serving as an initial test for buyer strength. ? If this level is successfully surpassed, the second target (TP2) at 4,460 will be in sight, where further resistance is expected. Traders should closely monitor market reactions at these levels, as any move beyond could signal a more bullish long-term trend. ?
MEMECOINS, ETFs, & CENTRAL BANK CLASHES ?? 1/8 Errol Musk’s “Musk It” memecoin wants to raise $200M for the Musk Institute—but it’s already down 52% since launch. Is this another flash in the pan, or can a Musk name (minus Elon) still spark ? gains? ? 2/8 The token ($MUSKIT) trades at $0.02, market cap at $25M. Celebrity-themed memecoins often burn hot then fizzle—yet Trump’s memecoin success sets a precedent. Could Errol replicate it? ?? 3/8 Big institutional move: The SEC just granted initial approval to Bitwise for a spot BTC/ETH ETF! Crypto goes mainstream. Allocations: 83% BTC and 17% ETH, mirroring market cap heft. ?? https://www.tradingview.com/x/hDMemFsU/ 4/8 Following similar green lights for Hashdex & Franklin Templeton’s dual-crypto ETFs, institutional adoption is revving up under Trump’s crypto-friendly SEC. Is a new rally on the horizon? ?? 5/8 Meanwhile, ECB President Christine Lagarde slammed the idea of Bitcoin in central bank reserves. ??? “It’s gotta be liquid, secure, & safe,” she says—BTC isn’t up to snuff. But the Czech National Bank? They’re open to exploring “other asset classes.” ?? 6/8 This Euro divergence contrasts with the US, where Trump’s digital asset push is fueling crypto-friendly moves. Central banks are split—some see BTC as an opportunity, others call it too volatile. ?⚖️ 7/8 Which storyline will shape 2025 the most? A) Memecoin Frenzy ? B) Spot ETFs ? C) Central Bank Debates ?️ Tell us! this is just the beginning… ⏳
seems like intel has double bottomed and ready to move higher
Look to short Today use higher time frames before entering any positions.
#SQT The price is moving in a descending channel on the 1-hour frame and is expected to continue upwards We have a trend to stabilize above the moving average 100 again We have a descending trend on the RSI indicator that supports the rise by breaking it upwards We have a support area at the lower limit of the channel at a price of 0.003222 Entry price 0.00360 First target 0.003449 Second target 0.003619 Third target 0.003743